The American Diabetes Association’s 79th Scientific Sessions is a five-day conference where researchers and healthcare professionals share the latest in diabetes research. More than 180 sessions and over 2,000 research presentations took place during the meeting on June 7-11 in San Francisco. During the meeting, diabetes experts shared data and research from clinical trials. Here […]
Medtronic, Tidepool ink deal for interoperable, automated insulin pump
Medtronic (NYSE:MDT) and nonprofit org Tidepool announced last week that the groups will work together to develop an interoperable, automated insulin delivery system. The medtech giant reported that it plans to build a Bluetooth-enabled MiniMed pump that is compatible with Tidepool’s Loop app, an open-source app for automated insulin delivery. Both companies plan to work […]
Medtronic touts huge real-world data set for MiniMed 670G
Patients using a smart insulin pump system made by Medtronic (NYSE:MDT) spent more time in a healthy blood glucose range, according to real-world data from more than 8 million patient days. The MiniMed 670G is designed to automatically track and adjust blood sugar levels, using a continuous glucose monitor, guiding patients toward a minimum level […]
Medtronic touts CGM study results
Medtronic (NYSE:MDT) today announced the results of its SMILE study that investigated the safety and effectiveness of its MiniMed 640G system with SmartGuard. The study was conducted in adults who have type 1 diabetes and are more prone to severe hypoglycemia. The SMILE study tested the MiniMed 640G insulin pump with SmartGuide to prevent low glucose […]
Medtronic, BCBS Minnesota ink value-based diabetes deal
Medtronic (NYSE:MDT) said today that it inked a deal with Blue Cross & Blue Shield of Minnesota on an outcomes-based program for diabetes patients. The plan gives BCBS Minnesota members access to Medtronic’s Guardian Connect continuous glucose monitor via a pharmacy benefit, with payments pegged to how long patients spend in a targeted blood glucose […]
Medtronic touts new targeted drug delivery study results
Targeted drug delivery and conventional medical management have shown to have a reduction in healthcare use and costs for cancer patients in comparison to conventional medical management alone, according to a new study from Medtronic. The study found that there were significant cost savings to payers and fewer inpatient visits with shorter inpatient stays. It […]
Medtronic responds to usability concerns for its MiniMed 670G insulin pump
Medtronic (NYSE:MDT) responded to a study presented this week which highlighted usability concerns with its MiniMed 670G automated insulin pump, writing that the company had “made many enhancements to the system since the study was done which would likely mitigate many of the issues experienced.” Earlier this week, physicians from Boston Children’s Hospital reported that nearly […]
Study examines usability of hybrid closed-loop insulin pump
Data from an 83-person study of Medtronic‘s (NYSE:MDT) MiniMed 670G hybrid closed-loop insulin pump showed that nearly one-fifth of participants stopped using the device after struggling with the technical demands of the system, researchers reported. Medtronic’s MiniMed 670G device is designed to automatically track and adjust a patient’s blood sugar levels by measuring blood glucose […]
U.K., French regulators probe safety of paclitaxel devices
Taking a note from the FDA, U.K. and French regulators are investigating the safety of paclitaxel devices for the treatment of peripheral artery disease. Last week, the U.K. Medicines and Healthcare Products Agency said it ordered an inquiry into the safety of these devices following the publication of a meta-analysis that suggested a heightened risk […]
Medtronic updates on corrected safety analysis for paclitaxel-coated balloon
Medtronic (NYSE:MDT) said last week that a revised safety analysis of its In.Pact drug-coated balloon has been accepted by the Journal of the American College of Cardiology. Last month, the medtech titan reported that a programming error inadvertently caused mortality data to be omitted from a statistical analysis involving the company’s paclitaxel-coated balloon. The announcement came […]
- 1
- 2
- 3
- …
- 13
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn